Immunovia announces completion of preferential rights issue

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Oct 19, 2016 at 11:15 AM

Immunovia announces completion of preferential rights issue of SEK 28.7 million, adding to previously SEK 189.9 million directed issue

(LUND, Sweden) ― Immunovia AB, the Swedish molecular diagnostics company, announces today that it has successfully completed its SEK 28.7 million rights issue of which the subscription period ended on Monday October 17th. The underwriters, who had guaranteed 52% of the rights issue, will thereby not be assigned any shares through their guarantee. 285,072 new shares, representing 86.5% of the rights issue of maximum 329,451 new shares, were subscribed with preferential rights. Demand for excess shares by rights holders amounted to 184,969 new shares, of which only 44,379 new shares could be allocated. The total demand for the offering amounted to approximately SEK 40.9 million, reflecting an oversubscription rate of 43%. The total amount, which is a record for a diagnostics company on Stockholm’s NASDAQ First North market, will be used primarily to initiate trials among diabetic patients which important new research shows are at high risk for pancreatic cancer. The trials will use Immunovia’s IMMrayTMPanCan-d blood -biomarker-based microarray test. Pancreatic cancer continues to have the lowest survival rates among the major forms of cancer. Today it is very clear that the main focus should be early detection of stages I & II pancreatic cancer in order to improve conditions for survival. Around 10% of pancreatic cancer cases have genetic and hereditary causes, and persons in this risk group can be clearly identified for regular surveillance. However, the vast majority (90%) of pancreatic cancer cases do not have the hereditary link and because the entire population cannot be monitored regularly, a first selection must be made. Immunovia CEO Mats Grahn commented: “Recent research shows that patients aged over 50 suffering from diabetes also have up to 8 times greater risk than normal of developing pancreatic cancer. There is a growing consensus that the size of this group makes it a logical target for surveillance. This has led both public authorities and health institutes in several countries to initiate research programs to identify and assess the best ways to reduce fatality through early detection of pancreatic cancer among the diabetes risk group. We believe PanCan -d provides the perfect diagnostic and surveillance tool and are already in active negotiations to bring together the various research strands into an international consortium.” The directed rights issue attracted several Swedish and Institutional investors including Handelsbanken Fonder, Ålandsbanken Fondbolag (which has been institutional investor in the company since the company's IPO in December 2015), E. Öhman J:or Fonder and Banque Internationale á Luxembourg. “We see these successful emmisions both as an indication of confidence in our technology and in our commercialization approach,” continued Grahn. “In additional to the diabetes program, we will deploy the new funds to expand the geographical markets in the commercialization of IMMrayTM PanCan-d for high risk individuals in familiar pancreatic cancer. A smaller portion will be used to develop tests from the IMMrayTM platform for other cancer forms and the autoimmune disease Lupus (SLE).” For further information, contact: Mats Grahn, CEO Immunovia AB Phone: +46 (0)70-532 02 30 E-mail: mats.grahn@immunovia.com About Immunovia Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com) Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Xavier Ochsner Opens State-of-the-Art Medical School

A New Era for Medical Education in New Orleans If you're familiar with New Orleans, you know it's a city defined by its vibrancy, culture, and resilience. Well, the Xavier Ochsner College of Medicine is adding to that narrative with the opening of their spanking new Center for Medical Education. It's a project that promises to shake things up in the best possible way for...

Wastewater Treatment Market to Hit $99.56B by 2031

The Changing Face of Wastewater Treatment Here's a whopper to chew on: the wastewater treatment services market ain't your grandfather's playground anymore. No sir, it's a fast-evolving arena aiming to swell to a whopping USD 99.56 billion by 2031. Now, how's that for growth? Mark my words, driven by stringent environmental regulations and thirst for clean water, this...

Nuix Names Lori Cornmesser to Head Global Partnerships

Nuix Shakes Things Up with New Leadership Nuix, a notable player in the investigative analytics and intelligence software space, just leveled up its game by bringing in Lori Cornmesser as the Global Vice President, Partner Ecosystems. This ain't your average hire. Cornmesser's been around the block—over 25 years, in fact—building and leading partner ecosystems...

Reagan Institute's New Fellowship: Academic Game-Changer

Aiming for an Academic Revival There’s hope on the horizon for academics wrestling to find their foothold among hallowed university halls. The Reagan Institute Society of Fellows is opening new doors for early career scholars. With heavyweight partners like Dartmouth and George Washington University joining forces, this is a solid lifeline amidst a sea of fading...

Bit Digital Shifts Focus: Q3 2026 Sees Strategic Moves

Bit Digital's Strategic Shakeup Ah, the digital gold rush is heating up again. Bit Digital, the outfit focused on Ethereum strategies and AI, dropped their financial results for Q3 2026. Picture a company at a strategic crossroads, shedding bitcoin mining baggage to grab hold of fresh opportunities in Ethereum staking and AI infrastructure. Bit Digital's earnings paint a...

Flor de Caña's Green Strategy Wins 2026 Stevie Award

Flor de Caña’s Environmental Triumph Seems like when folks think of premium rum, they might wanna start picturing not just smooth sips but a green commitment that runs deep. Flor de Caña has bagged a Stevie Award for their solid 'Net Zero Strategy of the Year.' This ain’t just any award; it's a nod from a respected crowd. A handshake from the business big shots who...

IBM's Sports Tech Challenge Crowns AI Innovator LivXP

Pioneering AI for Fan Engagement The big leagues of sports tech are buzzing, as IBM has just announced LivXP as the standout winner of their Sports Tech Startup Prize Challenge at the dynamic Web Summit Lisbon 2026. If there's one thing to remember, it's that this isn't just any accolade. This is a nod from IBM—an institution that's rubbed elbows with the giants of...

Brigham Nurses Secure Contract, Avoid Historic Strike

Victory for Brigham Nurses: Tentative Contract Reached Against a backdrop of looming unrest, over 4,000 registered nurses at Brigham and Women's Hospital have inked a tentative contract with Mass General Brigham. This isn't just a deal—it's relief to a near-crisis that would have kicked off with an open-ended strike. Standoff Averted at the Eleventh Hour How about...

Poolwerx Expands in Florida: Matt Feldt's Bold Move

A New Wave in Northeast Florida Bet you didn't expect to hear about pool care while sipping your morning coffee, but here we are. Poolwerx, the heavyweight champion in the pool service world, is pumping up its presence in the Northeast Florida landscape. Guess who’s the man behind this expansion? Matt Feldt, a Navy vet who’s traded in sonar for skimmers, has opened...

Tax Strategies for Small Businesses Before Year-End

Understanding the Importance of Year-Round Tax Planning Every small business owner dreads the tax season—like a thunderstorm on a picnic day. But here's a nugget from Paul Kersten, an Accounting and Tax whiz in Shawano, Wisconsin: don't wait until April to sort your taxes. By then, it's all receipts and regrets. Instead, consider tax planning as a year-long vigil. Why?...